M.D., M.B.A, Chief Business Officer, HealthTell, Inc.
Dr. Bright currently serves as HealthTell’s Chief Business Officer. Isaac is an entrepreneurial physician with a robust track-record building shareholder value and delivering transactional success for more than a decade. Following completion of his MD at Stanford University School of Medicine, Isaac served as Financial Analyst at CIBC World Markets in 2004. Dr. Bright was an esteemed Howard E. Mitchell Fellow at The Wharton School from 2004-2006. Isaac joined the Medtronic Corporate Development team in 2006, and quickly progressed to more complete deal leadership responsibilities, becoming Director of Business Development for Medtronic Neuromodulation in 2008. Capitalizing on his broad, blue-chip deal experiences, Dr. Bright joined the Executive Leadership of QuantaLife, Inc. in 2009 and led the Company’s financing and strategic transaction initiatives through the successful trade-sale to Bio-Rad Laboratories. Isaac became a Partner with Merieux Developpement in 2012, supporting the launch of a 150M Euro investment vehicle and leading investments in diagnostics, medical devices, and synthetic biology. In 2015, Dr. Bright served as VP, Corporate Development for Synthetic Biologics (NYSE:SYN), prior to assuming his leadership role at HealthTell, Inc.
Presentation Title and Company Description
Immunotherapy Showcase: Building Better Biotherapeutics: Insights into Molecular Interface Interactions
HealthTell is the innovator of massively diverse chemical libraries deployed to provide unique insights into the universe of biomolecular interactions. Our Rational Discovery programs leverage high-resolution binding insights to increase productivity of monoclonal antibody discovery research.